|
|
Bristol-Myers Squibb Co.
|
 |
||||||||
|
 |
  |
 |
|
|
||
 |
 |
 
|
return to message board, top of board |
Strong Buy
Re: BMS returns $475M IL-12 oncology asset to Dragonfly’s pond when you take positions in many early stage assets, not all of them work out? interesting that this particular IL-12 agent does not merit further clinical trials but better/cheaper to cut bait early! where is the turmoil? |
||||||||||||
|
|
return to message board, top of board |
